Gynetics' Preven

Emergency contraceptive could be considered for Rx-to-OTC switch in the coming years, the company indicates. The Rx kit, which includes four levonorgestrel .25 mg/ethinyl estradiol .05 mg pills as well as a pregnancy test and a patient information book, received FDA approval Sept. 2. Speaking at a same-day teleconference, Gynetics Chairman Roderick Mackenzie did not express an immediate desire to pursue a switch, citing market research showing women value the chance for product reimbursement and physician consultation, but said the company would "monitor this together with FDA for the next year or two. As we learn more, we are going to readdress the situation of whether going over-the-counter is appropriate." Rx Preven will be available nationwide in late September; a print/radio consumer ad campaign is planned for October. FDA has shown mild interest in oral contraceptives as switch candidates. An advisory meeting on the topic was scheduled for February 1993, but was postponed to gather input from interested groups...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Test H1 Heading

Test H1 Story

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

More from Pink Sheet

Test FDA Voucher Program Approvals Will Come From Product Centers, But Ambiguity Lingers

 
• By 

It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.

COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’

 
• By 

Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’

Nancy Tests New Podcast Template

 

Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.